Sector News

Allergan CFO retiring even as company faces 'negative sentiment'

September 25, 2017
Life sciences

Allergan CFO Tessa Hilado says she has done what she promised for Allergan and so now intends to retire. But the timing of her departure comes at a tricky time for the pharma, which has seen its shares fall in the face of its legal battle over Restasis patents and its out-of-left-field deal with a Mohawk tribe to shield them.

The company said today that Hilado, which came to Allergan three years ago, is retiring but agreed to stay on until her replacement is named.

Hilado, who came to the company with decades of finance experience, oversaw the company’s transformative deal to buy Allergan and its subsequent, $40.5 billion sale of its generics business to Teva, CEO Brent Saunders pointed out.

But news of the departure comes at an awkward time for the company. Two weeks Allergan caught investors by surprise with its announcement that it had transferred key Restasis intellectual property to the Saint Regis Mohawk Tribe. It claimed the maneuver would protect the patents from inter partes review challenges at the U.S. patent office because as a sovereign nation the tribe can claim immunity. Allergan was already battling generic companies in court over patent protection for Restasis, which is Allergan’s second-best selling drug with sales of about $1.5 billion last year.

But instead of instilling confidence, Allergan has seen its shares fall on news of the deal with the tribe and the immediate blowback that erupted.

On top of that, there have some pipeline setbacks, like Friday’s announcement that the FDA had delivered it a Refusal to File for its application to extend the use of antipsychotic drug Vraylar. That caught Wells Fargo analyst David Maris by surprise, given that Allergan just weeks ago touted the indication as as a potential growth driver without any mention that the FDA might have concerns, he told clients in a note today.

“The last few weeks have been challenging for AGN shares and we believe this news, which while only likely a minor negative by itself, only adds to already negative sentiment,” Maris wrote.

But to Bernstein analyst Ronny Gal, the timing is of Hilado’s exit is “excellent,” in a note to investors. Given that it was a person decision to retire, it shouldn’t be a negative and he sees the company poised for a rebound.

Allergan offered up some reassurance to investors today with the announcement of a new $2 billion share buyout program and a couple of affirmations. It reaffirmed guidance of for Q3 and the year, and then affirmed its commitment to its investment-grade credit ratings and debt paydown strategy. That came right before it announced it was losing its CFO.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach